MA53007A - Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives - Google Patents
Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénérativesInfo
- Publication number
- MA53007A MA53007A MA053007A MA53007A MA53007A MA 53007 A MA53007 A MA 53007A MA 053007 A MA053007 A MA 053007A MA 53007 A MA53007 A MA 53007A MA 53007 A MA53007 A MA 53007A
- Authority
- MA
- Morocco
- Prior art keywords
- age
- degenerative diseases
- pharmaceutical association
- pharmaceutical
- association
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180906 | 2018-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53007A true MA53007A (fr) | 2021-05-05 |
Family
ID=62837788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053007A MA53007A (fr) | 2018-06-29 | 2019-07-01 | Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12090124B2 (fr) |
| EP (2) | EP4257189A3 (fr) |
| JP (3) | JP2021530459A (fr) |
| KR (3) | KR102846956B1 (fr) |
| CN (1) | CN112654367B (fr) |
| AU (2) | AU2019294573B2 (fr) |
| BR (1) | BR112020026456A2 (fr) |
| CA (1) | CA3104397C (fr) |
| EA (1) | EA202190151A1 (fr) |
| ES (1) | ES2965834T3 (fr) |
| IL (2) | IL309939A (fr) |
| MA (1) | MA53007A (fr) |
| PL (1) | PL3813882T3 (fr) |
| SG (1) | SG11202012731WA (fr) |
| WO (1) | WO2020002715A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240049717A (ko) | 2022-10-07 | 2024-04-17 | 순천향대학교 산학협력단 | 플로리진의 노화 관련 질환의 예방 또는 치료 용도 |
| CN120152703A (zh) | 2022-11-07 | 2025-06-13 | 再青春生物医药股份有限公司 | 二甲双胍微型片剂 |
| JP2025540927A (ja) | 2022-11-07 | 2025-12-17 | リジュベネイト バイオメッド エヌブイ | ガランタミン小型錠剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| EP1150695B1 (fr) * | 1999-01-11 | 2007-02-28 | Atanas Russinov Djananov | Complement alimentaire vegetal servant a ameliorer la resistance musculaire et l'endurance d'athletes |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| MX2008012479A (es) * | 2006-03-29 | 2009-08-13 | Velacor Therapeutics Pty Ltd | Tratamiento de enfermedades neurodegenerativas. |
| AU2008302190A1 (en) * | 2007-09-18 | 2009-03-26 | Stephen Wills | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors |
| US20130217778A1 (en) * | 2010-07-21 | 2013-08-22 | Herman H. Vandenburgh | Methods and compositions for the improvement of skeletal muscle function in a mammal |
| CN103860532B (zh) * | 2014-03-11 | 2016-02-17 | 贡岳松 | 美金刚和二甲双胍的复方药用组合物及其制备方法 |
| CN104623671B (zh) * | 2015-02-09 | 2017-11-17 | 徐云根 | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 |
-
2019
- 2019-07-01 KR KR1020247036684A patent/KR102846956B1/ko active Active
- 2019-07-01 EA EA202190151A patent/EA202190151A1/ru unknown
- 2019-07-01 JP JP2020572917A patent/JP2021530459A/ja active Pending
- 2019-07-01 CA CA3104397A patent/CA3104397C/fr active Active
- 2019-07-01 KR KR1020217002941A patent/KR102576433B1/ko active Active
- 2019-07-01 SG SG11202012731WA patent/SG11202012731WA/en unknown
- 2019-07-01 MA MA053007A patent/MA53007A/fr unknown
- 2019-07-01 EP EP23181463.3A patent/EP4257189A3/fr not_active Withdrawn
- 2019-07-01 IL IL309939A patent/IL309939A/en unknown
- 2019-07-01 PL PL19734401.3T patent/PL3813882T3/pl unknown
- 2019-07-01 US US17/255,662 patent/US12090124B2/en active Active
- 2019-07-01 ES ES19734401T patent/ES2965834T3/es active Active
- 2019-07-01 CN CN201980043961.1A patent/CN112654367B/zh active Active
- 2019-07-01 KR KR1020237030214A patent/KR20230145380A/ko not_active Ceased
- 2019-07-01 AU AU2019294573A patent/AU2019294573B2/en active Active
- 2019-07-01 BR BR112020026456-3A patent/BR112020026456A2/pt unknown
- 2019-07-01 IL IL279732A patent/IL279732B2/en unknown
- 2019-07-01 WO PCT/EP2019/067645 patent/WO2020002715A1/fr not_active Ceased
- 2019-07-01 EP EP19734401.3A patent/EP3813882B1/fr active Active
-
2022
- 2022-06-15 AU AU2022204173A patent/AU2022204173A1/en not_active Abandoned
-
2023
- 2023-02-03 JP JP2023015268A patent/JP7542662B2/ja active Active
-
2024
- 2024-08-01 US US18/791,912 patent/US20240390302A1/en active Pending
- 2024-08-16 JP JP2024136978A patent/JP7832631B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4003369A4 (fr) | Dérivé d'adénosine et composition pharmaceutique le comprenant | |
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| EP3868409A4 (fr) | Connecteur destiné à être utilisé dans un conjugué médicament anticorps et applications de connecteur | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| EP3357508A4 (fr) | Préparation pharmaceutique d'anticorps anti-pd-1 stable et application de celle-ci dans un médicament | |
| MA53007A (fr) | Association pharmaceutique destinée à être utilisée dans des maladies liées à l'âge et/ou dégénératives | |
| EP3655531A4 (fr) | Séquençage d'acides nucléiques associés à l'isolement exosomal chez des patients atteints de glioblastome multiforme | |
| EP3572050A4 (fr) | Agent de traitement d'excréments destiné à être utilisé dans des colostomies | |
| EP3639833A4 (fr) | Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation | |
| LT3586837T (lt) | Kompozicijos, apimančios aminorūgštis, skirtos panaudoti kepenų ligų prevencijai ir gydymui | |
| EP3901138A4 (fr) | Composé destiné à être utilisé dans des maladies rétiniennes | |
| DK3842423T3 (da) | 3-azabicyclo[3,1,1]heptanderivat og farmaceutisk sammensætning omfattende denne | |
| EP3523281A4 (fr) | Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| EP3645120A4 (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| EP3960858A4 (fr) | Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison | |
| EP3877028A4 (fr) | Appareil d'assistance respiratoire et/ou composants associés | |
| EP3766503A4 (fr) | Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires | |
| EP3452051A4 (fr) | Composition comprenant du hmos destinée à être utilisée dans le traitement de l'hypersensibilité et/ou de la douleur viscérale médiée par les mastocytes | |
| EP3472133A4 (fr) | Inhibiteurs de perk et utilisations associées dans le traitement de maladies associées à des protéines sujettes à l'agrégation | |
| EP3752088A4 (fr) | Plateforme et système destinés à être utilisés dans des procédures thérapeutiques | |
| EP3813868A4 (fr) | Régimes posologiques pour l'inhibition ciblée de tgf-? destinée à être utilisée dans le traitement du cancer chez des sujets vierges de tout traitement | |
| MA54936A (fr) | Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie | |
| EP3615022C0 (fr) | Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires | |
| EP3768263C0 (fr) | Administration continue d'une composition pharmaceutique pour le traitement de troubles neurodégénératifs |